N/A
N=30
Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
Nasal Polyps · Aspirin-exacerbated Respiratory Disease
Bottom Line
View on ClinicalTrials.gov: NCT05672030 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Nov 2025
Primary outcome: Primary: Number of Participants With Nasal Polyp Plasma Cell Transcriptome — 10; 10; 10 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Non-Interventional (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Brigham and Women's Hospital
- Primary completion
- Dec 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Nasal Polyp Plasma Cell Transcriptome |
10; 10; 10 | — |
| SECONDARY Number of Participants With Functional Readouts of IL-5Ra on Nasal Polyp Plasma Cells. |
10; 10; 10 | — |
| SECONDARY Number of Patients for Whom IL-5Ra Signaling on Nasal Epithelial Cells Can be Analyzed |
10; 10; 10 | — |
Summary
The overarching hypothesis of this proposal is that IL-5 acts on multiple sinus tissue cell types, including plasma cells and epithelial cells, to promote immune dysregulation, and that inhibition of IL-5 affects several relevant effector pathways that lead to clinical benefit.
Eligibility Criteria
Inclusion Criteria
- AERD, CRSwNP, healthy controls
Exclusion Criteria
- Not on any systemic steroids or respiratory biologics at time of surgery
Data sourced from ClinicalTrials.gov (NCT05672030). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.